StockNews.AI
APVO
StockNews.AI
137 days

Aptevo Therapeutics Announces the Closing of $2.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules

1. Aptevo Therapeutics closed a simultaneous stock and warrant offering at $1.19 per share. 2. The offering may impact APVO’s market perception and liquidity.

2m saved
Insight
Article

FAQ

Why Neutral?

While the offering raises capital, it may dilute existing shareholders' equity. Historically, similar offerings often lead to fluctuations in stock prices due to market sentiment.

How important is it?

This article provides key information about new capital raising, which can influence investor decisions regarding APVO's future.

Why Short Term?

Investors may react quickly to dilution concerns, affecting the stock price in the near term. Over time, if the funds are effectively used, the long-term impact could shift positively.

Related Companies

CLVSAXLASLDB
SEATTLE, WASHINGTON / ACCESS Newswire / April 4, 2025 / Aptevo Therapeutics Inc. (Nasdaq:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technologies, announced the closing of its previously announced offering of 1,764,710 shares of the Company's common stock in a registered direct offering and warrants to purchase up to 3,529,420 shares of common stock in a concurrent private placement (together with the registered direct offering, the "offering") at a combined purchase price of $1.19 per share and accompanying warrant. The warrants issued pursuant to the concurrent private placement have an exercise price of $1.19 per share, will be exercisable upon the receipt of stockholder approval and will expire 5 years from the date of stockholder approval.

Related News